Dec. 6 (Bloomberg) -- U.S. regulators pushed for more studies of Johnson & Johnson’s Ortho Evra birth control patch after determining research on its association with an increased risk of blood clots isn’t definitive.
The Food and Drug Administration asked outside advisers at a meeting scheduled Dec. 9 to review and discuss studies that link the Ortho Evra patch with an increased risk of blood clots, according to an agency staff report released today. The agency is not required to follow the advisers’ recommendations.
--Editor: Andrew Pollack
To contact the reporter on this story: Anna Edney in Washington at firstname.lastname@example.org.
To contact the editor responsible for this story: Adriel Bettelheim at email@example.com.